	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	409.84	468.64	538.35	463.99	418.27	400.04	372.41	321.89	339.33	548.12	598.65	555.51	601.45	647.89	769.60	811.28
Cost of Operating Revenue	256.89	302.30	346.95	322.05	287.45	267.33	238.91	215.93	206.32	376.07	418.98	375.47	397.75	422.90	412.95	423.67
Gross Profit	152.95	166.33	191.40	141.94	130.82	132.71	133.50	105.96	133.01	172.05	179.66	180.04	203.70	224.99	356.65	387.61
Gross Margin	37.3	35.5	35.6	30.6	31.3	33.2	35.8	32.9	39.2	31.4	30.0	32.4	33.9	34.7	46.3	47.8
Total Operating Expenses	333.50	383.49	443.55	420.81	378.79	389.58	366.77	323.35	330.53	529.62	570.07	527.61	568.29	606.86	647.99	671.45
Operating Profit	76.34	85.15	94.80	43.18	39.48	10.46	5.64	-1.45	8.81	18.50	28.58	27.90	33.16	41.02	121.61	139.83
Operating Margin	18.6	18.2	17.6	9.3	9.4	2.6	1.5	-0.5	2.6	3.4	4.8	5.0	5.5	6.3	15.8	17.2
Financing Income/(Expense) - Net	-25.65	-22.60	-25.95	-40.95	-37.60	-34.37	-35.43	-25.41	-13.34	-13.02	0.34	8.93	10.58	11.11	-0.04	-0.03
Profit before Taxes	50.85	62.84	69.08	2.65	3.51	-21.64	-27.53	-29.73	-8.04	48.55	36.41	37.93	44.64	71.83	134.15	151.59
Income Taxes	3.78	5.53	4.78	-2.51	1.81	-4.56	3.16	-1.15	1.96	-13.21	-4.32	11.36	16.15	26.51	31.36	35.43
Profit after Tax	47.08	57.31	64.30	5.16	1.70	-17.08	-30.69	-28.58	-10.00	61.77	40.72	26.57	28.49	45.31	-	116.18
PAT Margin	11.5	12.2	11.9	1.1	0.4	-4.3	-8.2	-8.9	-2.9	11.3	6.8	4.8	4.7	7.0	-	14.3
EPS - Basic - ex Extraordinary Items	51.22	58.80	57.17	4.51	1.48	-13.84	-24.87	-23.15	-8.10	50.04	30.86	19.87	21.31	33.90	76.90	86.92
EPS - Diluted - ex Extraordinary Items	51.22	58.80	57.17	4.51	1.48	-13.84	-24.87	-23.15	-8.10	50.04	30.86	19.87	21.31	33.90	76.90	86.92
EBIT	76.34	85.15	94.80	43.18	39.48	10.46	5.64	-1.45	8.81	18.50	28.58	27.90	33.16	41.02	121.61	139.83
EBITDA	100.20	118.23	135.02	89.18	81.16	50.72	39.47	32.53	40.82	53.78	62.11	60.20	59.60	63.53	147.28	166.09
EBITDA Margin	24.4	25.2	25.1	19.2	19.4	12.7	10.6	10.1	12.0	9.8	10.4	10.8	9.9	9.8	19.1	20.5

Balance Sheet

Abridged

Understanding Balance Sheet

Venus Remedies Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	169.63	225.58	272.12	233.21	275.95	259.41	263.77	265.43	294.00	234.03	278.04	322.96	359.52	451.72	395.20
Long-Term Investments	-	-	-	-	-	-	-	1.88	3.25	1.93	2.19	-	0.02	0.02	163.82
Property Plant & Equipment - Net	200.20	245.24	281.03	282.85	282.54	279.41	273.34	261.20	208.57	190.08	178.24	162.81	154.41	151.09	188.98
Total Non-Current Assets	404.40	491.97	562.24	607.85	528.77	505.60	487.08	467.39	349.77	321.82	301.78	278.12	267.30	264.00	458.50
Total Assets	574.03	717.55	834.35	841.06	804.72	765.00	750.85	732.83	643.77	555.85	579.82	601.08	626.82	715.72	853.70
Total Current Liabilities	153.22	191.25	210.99	162.83	192.02	196.81	230.47	263.62	224.58	97.45	92.74	82.57	79.42	136.29	161.76
Long Term Debt	99.13	129.12	139.98	202.29	191.05	161.82	137.44	116.02	72.05	46.83	38.68	38.68	38.68	-	11.05
Total Non-Current Liabilities	113.51	147.18	161.75	221.55	212.99	179.52	158.47	136.68	95.82	58.12	46.63	58.17	59.86	18.48	28.20
Total Liabilities	266.74	338.42	372.74	384.38	405.00	376.33	388.94	400.30	320.40	155.57	139.37	140.74	139.27	154.77	189.96
Total Shareholders' Equity	307.29	379.13	461.61	456.68	399.72	388.67	361.91	332.52	323.37	400.28	440.45	460.34	487.55	560.95	663.75
Total Equity	307.29	379.13	461.61	456.68	399.72	388.67	361.91	332.52	323.37	400.28	440.45	460.34	487.55	560.95	663.75
Total Liabilities & Equity	574.03	717.55	834.35	841.06	804.72	765.00	750.85	732.83	643.77	555.85	579.82	601.08	626.82	715.72	853.70

Cash Flow

Abridged

Understanding Cash Flow Statement

Venus Remedies Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	80.69	103.71	106.50	51.08	25.56	16.55	6.72	8.92	45.46	64.28	64.27	63.04	53.47	66.39	118.26
Working Capital - Increase/(Decrease)	-39.14	-51.41	-53.65	-18.40	-13.04	9.96	-7.52	14.33	20.82	60.67	-22.63	-24.63	-12.11	24.53	37.52
Net CF from Operating Activities	41.55	52.31	52.86	32.68	12.53	26.51	-0.81	23.25	66.28	124.95	41.64	38.41	41.36	90.92	157.33
Capital Expenditures - Net	95.03	104.05	94.67	67.42	50.46	18.29	11.78	9.92	7.78	-57.57	13.29	7.74	13.04	17.88	37.51
Net CF from Investing Activities	-95.03	-104.05	-94.91	-67.44	2.55	-18.56	-11.73	-11.57	-5.09	56.37	-17.44	-52.73	-11.37	-80.79	-183.71
Stock - Issuance/(Retirement) - Net	17.25	7.96	19.10	-	-	-	-	-	-	13.75	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	31.23	42.42	25.78	33.96	-11.62	-11.46	-6.99	-12.80	-60.94	-168.97	-9.02	-0.45	-0.99	-0.95	-1.69
Net Cash Flow from Financing Activities	53.30	55.15	40.10	33.96	-11.62	-11.46	-6.99	-12.85	-61.34	-155.23	-9.30	-0.45	-0.99	-0.95	-2.53
Free Cash Flow to Equity	-22.25	-9.32	-16.04	-0.78	-49.56	-3.24	-19.58	0.53	-2.44	13.55	19.33	30.21	27.33	72.09	118.12
Free Operating CF net dividend	-53.48	-51.74	-41.81	-34.74	-37.94	3.72	-14.08	13.32	58.50	117.22	27.93	30.59	27.84	72.84	119.62
Free Operating CF	-53.48	-51.74	-41.81	-34.74	-37.94	3.72	-14.08	13.32	58.50	117.22	27.93	30.59	27.84	72.84	119.62

Business Segment Analysis

FY End:

Mar 25

Venus Remedies Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharamaceuticals (100.0%)₹ 18.08 Cr

Revenue / Sales

Pharamaceuticals (100.0%)₹ 647.89 Cr

Assets

Pharamaceuticals (100.0%)₹ 715.72 Cr

Operating Income

Pharamaceuticals (100.0%)₹ 41.02 Cr

Regional Segment Analysis

Venus Remedies Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Venus Remedies Ltd.

Historical Segment Analysis

Track how Venus Remedies Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharamaceuticals	8	14	18

Frequently Asked Questions

What is the revenue of Venus Remedies Ltd.?

The latest trailing twelve month revenue of Venus Remedies Ltd. is ₹ 811.28 Cr, reflecting a 1-year growth of 20.87% and a 3-year CAGR of 16.92%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Venus Remedies Ltd.?

The latest trailing twelve month net profit (PAT) of Venus Remedies Ltd. is ₹ 116.18 Cr, with a 3-year earnings CAGR of 77.25%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Venus Remedies Ltd.?

The trailing twelve month EBITDA of Venus Remedies Ltd. is approximately ₹ 139.83 Cr (based on an operating margin of 17.24%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Venus Remedies Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Venus Remedies Ltd. is 86.92. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Venus Remedies Ltd.?

The debt-to-equity ratio of Venus Remedies Ltd. stands at 0.02. The interest coverage ratio is 3,313.52x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Venus Remedies Ltd.?

The estimated book value per share of Venus Remedies Ltd. is 508.66 (derived from a P/B ratio of 3.08 and market price of ₹ 1,568.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Venus Remedies Ltd.?

The trailing twelve month operating cash flow of Venus Remedies Ltd. is ₹ 157.32 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Venus Remedies Ltd. report consolidated or standalone financials?

Venus Remedies Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.